Inaedis’ Rapid Room Temperature Aerosol Dehydration (RTAD) converts liquid biologics into stable powders at ambient conditions. By eliminating heat and freezing, RTAD preserves activity and enables three key formats: suspensions, inhalable powders, and reconstitutable injections.
Technology
Overview
How RTAD Works
RTAD creates a thin liquid film that disintegrates into ultra-fine droplets, which dry in tens of milliseconds at room temperature. These particles are collected either as dry powders or directly into liquid to form suspensions. The process dramatically reduces thermal and mechanical stress, maintaining biological activity while also providing precise control over particle size and composition.
Why RTAD Is Different
Compared to Other Technologies
- Lyophilization (freeze-drying): Requires freezing, lyoprotectants, long batch cycles, and high RTAD operates at room temperature with minimal excipients, continuous processing, and drying times 10-100× faster.
- Traditional spray drying: Relies on 100-250 °C heat, generates larger droplets, and damages fragile biologics. RTAD dries droplets in tens of milliseconds at room temperature, producing amorphous, highly soluble powders while preserving
- Other suspension approaches: Conventional suspension methods require powder handling and resuspension steps, creating aseptic challenges. RTAD can directly produce suspensions in one step, avoiding extra handling and reducing contamination
Compared to Subcutaneous Enzyme Approaches
- Other technologies use hyaluronidase enzymes to temporarily break down tissue, enabling larger injection volumes.
- RTAD takes a different approach: It produces ultra-high concentration, low-viscosity suspensions that allow standard 1 mL injections without This avoids the large volumes that make hyaluronidase necessary and enables rapid injections both in the clinic and at home.